Combined treatment, based on lysomustine administration with mesenchymal stem cells expressing cytosine deaminase therapy, leads to pronounced murine Lewis lung carcinoma growth inhibition.

ConclusionsOur data indicates that the combination CDA/UPRT‐expressing AT‐MSCs with lysomustine has a superior antitumor effect in murine lung carcinoma model, in comparison with monotherapies with transfected AT‐MSCs or lysomustine alone, possibly because of synergistic effect of the combination therapy.

Source: The Journal of Gene Medicine - June 30, 2016 Category: Genetics & Stem Cells Authors: Lyudmila S. Krassikova, Saida S. Karshieva, Ivan B. Cheglakov, Alexander V. Belyavsky Tags: Research Article Source Type: research